ANTIBODIES, KITS, AND REAGENTS FOR THE STUDY OF

Cellular Metabolism
Cellular Metabolism

Organisms continually process nutrients for energy production and creation of new biomass. The study of how and when substrates are metabolized is central to the study of cell proliferation, growth, survival, and tumor progression.

Glucose is the primary energy source for most cells of the body, and the maintenance of glucose homeostasis is an essential physiological process regulated by hormones. An elevation in blood glucose levels during feeding stimulates insulin release from pancreatic β-cells. Insulin is a hormone that regulates glucose and lipid metabolism throughout the body. It stimulates glucose uptake in muscle and adipose tissue, increases glycogen synthesis and suppresses gluconeogenesis in the liver, and promotes triglyceride synthesis and suppression of lipolysis in adipose tissue. Insulin binding to the insulin receptor (IR) triggers signaling through Akt to cause translocation of Glut4-containing vesicles from intracellular compartments to the cell surface, thereby allowing glucose to enter the cell resulting in decreased blood glucose concentrations. In addition, IR-mediated activation of Akt and MAPK results in cell growth, protein synthesis, and survival. An ineffective response to insulin produces the insulin resistance associated with type 2 diabetes (T2D), metabolic syndrome, and some forms of obesity.

Once glucose enters the cell, it is metabolized via glycolysis and the Krebs cycle for optimal ATP production. However, this metabolic signature is disrupted in some cancer cells, which display a shift towards ATP production via glycolysis alone. This phenomenon is called aerobic glycolysis or the Warburg effect. Signaling proteins such as Akt, AMPK, MAPK, p53, and c-Myc influence aerobic glycolysis by regulating expression and activity of key metabolic enzymes.

As blood glucose concentrations fall, the hormone glucagon is released from pancreatic α-cells. Glucagon has the opposite effect of insulin—it promotes glycogenolysis and gluconeogenesis in the liver in order to sustain optimal blood glucose levels. In addition to the actions of glucagon, the serine/threonine kinase AMPK also plays an important role in maintaining cellular energy levels. AMPK is activated by increases in the AMP:ATP and/or ADP:ATP ratios, as a result of low ATP levels. AMPK functions to restore cellular energy levels by promoting ATP-generating processes such as glucose transport, fatty acid oxidation, and glycolysis, while inhibiting ATP-consuming processes such as protein and lipid synthesis. AMPK’s role as a master metabolic regulator has made it the focus of intense research efforts within the fields of cancer and metabolic and cardiovascular diseases. For example, the AMPK activator, metformin, is one of the most commonly prescribed drugs for the treatment of T2D.

CST has antibodies, kits, and reagents for each stage of the experimental process.

<table>
<thead>
<tr>
<th>Research tools for the study of cellular metabolism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Antibodies</strong></td>
</tr>
<tr>
<td>Over 740 primary antibodies directed against more than 300 protein targets. The collection is continually expanding, so please check our website frequently for a complete, up-to-date product list.</td>
</tr>
</tbody>
</table>

| **PTMScan Kits and Services**                        |
| PTMScan® Kits and Services utilize motif antibodies and LC-MS/MS technology to generate quantitative profiles of hundreds to thousands of proteins containing a particular type of post-translation modification. |

| **Antibody Sampler Kits**                            |
| Sampler kits allow for the simultaneous analysis of multiple nodes in a pathway of interest or modification sites within a protein of interest. |

| **ELISA Kits and Antibody Arrays**                   |
| PathScan® ELISA Kits enable you to scale up your analysis to a 96-well format (384-well plates are also available on a custom basis), while antibody arrays allow you to monitor multiple pathway nodes in parallel using sandwich assays in a slide- or membrane-based array. |

| **SignalSilence siRNA**                              |
| Rigorously validated SignalSilence® siRNAs can be used to selectively reduce the expression of a protein of interest. |

| **Chromatin IP Kits and Reagents**                   |
| SimpleChIP® and SimpleChIP® Plus Chromatin IP Kits, ChIP-validated antibodies, control PCR primers, and companion products needed to perform successful ChIP assays are available to explore protein-DNA interactions. |

| **Experimental Controls**                            |
| Control cell extracts, control proteins, blocking peptides, and isotype controls are available to help you verify antibody specificity. |

| **Companion Products**                               |
| Secondary antibodies, loading controls, buffers, dyes, chemical modulators, detection reagents, protease inhibitors, and peptide standards are available to support your protocol. |

| **Custom Products**                                  |
| Our custom antibody department will work with you if you require a product in a specific size or formulation for your particular assay platform or if you need a product validated using a specific measure or assay. |
**TARGET LOCALIZATION**

Antibodies, both conjugated and unconjugated, to assess subcellular localization of key metabolic targets

**FoxO3a (D19A7) Rabbit mAb #12829:**
Confocal IF analysis of PC-3 cells, treated with Human Insulin-like Growth Factor I (hIGF-I) #8917 (A) or LY294002 #9901 (B), using #12829 (green). Actin filaments were labeled with Dyl554 phalloidin (red). IHC analysis of paraffin-embedded human breast carcinomas (C) using #12829.

**QUANTITATIVE ASSAYS**

ELISA kits, antibody arrays, chromatin IP kits, and other cell-based assays for quantitative analysis

PathScan® Akt Signaling Antibody Array Kit (Fluorescent Readout) #9700:
MCF7 cells were grown to 85% confluency and then serum starved overnight. Cells were either untreated or treated with Human Insulin-like Growth Factor I (hIGF-I) #8917 (100 ng/ml, 20 min). Cell extracts were prepared and analyzed with #9700. Images were acquired using the LI-COR® Biosciences Odyssey® imaging system. Graph shows quantification of results. Pixel intensity was quantified using the LI-COR® Image Studio v2.0 array analysis software.

**Target Map:** Using PathScan® Akt Signaling Antibody Array Kit (Fluorescent Readout) #9700.
**CELL-BASED ASSAYS**

Second messenger, proliferation, viability, and cell death assays to monitor cell health and signaling in a cell population.

**Cyclic AMP XP® Assay Kit #4339**: Treatment of CHO cells with Forskolin #3828 increases cAMP concentration as detected by #4339. CHO cells were seeded at 4x10^5 cells/well in a 96-well plate and incubated overnight. Cells were either left untreated or pretreated with 0.5 mM IBMX for 30 min prior to forskolin treatment (15 min) and lysed with 1X Cell Lysis Buffer #9803. The absorbance values (left) and percentage of activity (right) are shown above. The percentage of activity is calculated as follows: % activity = 100x[(A - A_{basal})/(A_{max} - A_{basal})], where A is the sample absorbance, A_{basal} is the absorbance at basal level (no forskolin), Forskolin directly activates adenylyl cyclases and increases cellular cAMP concentration. IBMX is a non-specific inhibitor of cAMP and cGMP phosphodiesterases and promotes accumulation of cAMP and cGMP in cells.

**EXPERIMENTAL CONTROLS**

Alter protein expression with controlled siRNA knockdown

**SignalSilence® AMPKα2 siRNA I #6620 and SignalSilence® AMPKα2 siRNA II #6630**: WB analysis of extracts from HeLa cells transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), #6620 (+), or #6630 (+), using AMPKα2 Antibody #2757 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The AMPKα2 Antibody confirms silencing of AMPKα2 expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.

**PROTEOMIC ANALYSIS**

PTMScan® Kits and Services for PTM profiling

**PTMScan Technology**

PTMScan® Technology is a proprietary proteomic method developed at Cell Signaling Technology designed to help researchers understand the role of post-translational modifications (PTMs) in both health and disease. This technology can be used to assess PTMs associated with a disease model system, detect substrates of novel signaling proteins, profile effects of a candidate therapeutic on a specific type of PTM, or identify novel biomarkers to predict therapeutic efficacy.

Learn more at www.cellsignal.com/proteomics
**Cellular Metabolism Targets**

WE’VE GOT IT COVERED

Our total and modification-specific antibody portfolio covers critical targets within metabolic pathways. Visit our website for a complete product listing.

| ABCC1 | ABCC1 | ABCC3 | ABCC4 | ABCG2 | ACAD9 | ACAT2 | AceCS1 | Acetyl-CoA Carboxylase | Phospho-Acetyl-CoA Carboxylase (Ser79) | Acetyl-CoA Carboxylase 1 | Acetyl-CoA Carboxylase 2 | ACO2 | ACSL1 | ADH1B | Adiponectin | AKR1C2 | Akt (pan) | Phospho-Akt (Thr308) | Phospho-Akt (Thr450) | Phospho-Akt (Ser473) | Akt1 | Phospho-Akt1 (Ser129) | Phospho-Akt1 (Ser473) | Akt2 | Phospho-Akt2 (Ser474) | Akt3 | Phospho-Akt3 (Ser472) | ALDH1A1 | Aldolase A | AMACR | AMPKα | Phospho-AMPKα (Thr172) | AMPKα1 | Phospho-AMPKα1 (Ser485) | Phospho-AMPKα1 (Ser485) | AMPKα2 | AMPKβ1 | Phospho-AMPKβ1 (Ser108) | Phospho-AMPKβ1 (Ser182) | AMPKβ2 | AMPKγ1 | AMPKγ2 | α-Amylase | ANT2/SLC25A5 | AQP2 | Arginase-1 | ARK5 | AS160 | Phospho-AS160 (Ser318) | Phospho-AS160 (Ser588) | Phospho-AS160 (Thr642) | ASCT2 | ATF-4 | ATGL | ATP Citrate Lyase | Phospho-ATP Citrate Lyase (Ser455) | ATPIF1 | BCAT1 | BCAT2 | C10BP | CA2 | CA9 | CA12 | CAD | Phospho-CAD (Ser1859) | Catalase | CCTa | C/EBPβ | Phospho-C/EBPβ (Thr235) | C/EBPδ | CLIC4 | COX IV | C-Peptide | CPT1A | CTMP | CTR1/SLC31A1 | CYP11A1 | CYP3A4 | DEPTOR/DEPDC6 | DHCR24/Seladin-1 | DJ-1 | DLAT | DLST | DPYD | Enolase-1 | Enolase-2 | eNOS | Phospho-eNOS (Ser113) | Phospho-eNOS (Thr495) | Phospho-eNOS (Ser1177) | ENPP1 | FAAH1 | FABP1 | FABP4 | Fatty Acid Synthase | FLCN | FoxC2 | FoxO1 | Phospho-FoxO1 (Thr24)/FoxO3a (Thr28) | Phospho-FoxO1 (Ser253) | Phospho-FoxO1 (Ser294) | Phospho-FoxO1 (Ser318/321) | Phospho-FoxO1 (Ser413) | FoxO3a | Phospho-FoxO3a (Ser253) | Phospho-FoxO3a (Ser294) | Phospho-FoxO3a (Ser318/321) | Phospho-FoxO3a (Ser413) | Fox04 | Phospho-Fox04 (Ser193) | FTH1 | Fumarase | Gab1 | Phospho-Gab1 (Tyr307) | Phospho-Gab1 (Tyr627) | Phospho-Gab1 (Tyr659) | Gab2 | Phospho-Gab2 (Ser159) | Phospho-Gab2 (Tyr452) | GAPDH | GβL | GFAT1 | GFAT2 | GLDC | Glucagon | Glucose-6-Phosphate Dehydrogenase | Glycogen Synthase | Phospho-Glycogen Synthase (Ser641) | GPX1 | Phospho-Grb10 (Ser476) | GSK-3α | Phospho-GSK-3α (Ser21) | GSK-3α/β | Phospho-GSK-3α/β (Ser21/9) | GSK-3β | Phospho-GSK-3β (Ser9) | Phospho-GSK-3β (Thr390) | hERG1a | Hexokinase I | Hexokinase II | HO-1 | HMOX2/HO-2 | HSL | Phospho-HSL (Ser563) | Phospho-HSL (Ser565) | Phospho-HSL (Ser660) | IDH1 | IDH2 | IGF-1 Receptor β | Phospho-IGF-I Receptor β (Tyr980) |
Phospho-IGF-I Receptor β (Tyr1131)
Phospho-IGF-I Receptor β (Tyr1131)/Insulin Receptor β (Tyr1146)
Phospho-IGF-I Receptor β (Tyr1135)
Phospho-IGF-I Receptor β (Tyr1135)/Insulin Receptor β (Tyr1150/1151)
Phospho-IGF-I Receptor β (Tyr1316)
IGFBP2
Insulin Receptor β
Phospho-Insulin Receptor β (Tyr1146)
Phospho-Insulin Receptor β (Tyr1150/1151)
Phospho-Insulin Receptor β (Tyr1345)
Phospho-Insulin Receptor β (Tyr1361)
Insulin
IRAP
IRS-1
Phospho-IRS-1 (panTyr)
Phospho-IRS-1 (Ser302)
Phospho-IRS-1 (Ser307)
Phospho-IRS-1 (Ser318)
Phospho-IRS-1 (Ser332/336)
Phospho-IRS-1 (Ser612)
Phospho-IRS-1 (Ser636/639)
Phospho-IRS-1 (Ser789)
Phospho-IRS-1 (Tyr895)
Phospho-IRS-1 (Ser1101)
Phospho-IRS-1 (Tyr1222)
IRS-2
Phospho-IRS-2 (panTyr)
LAMTOR1/C11orf59
LAMTOR2/ROBLD3
LAMTOR3/MAPKSP1
LAMTOR4/C7orf59
LARS
LAT1
LDHA
Phospho-LDHA (Tyr10)
LDHA/LDH C
LIPIN1
LKB1
Phospho-LKB1 (Thr189)
Phospho-LKB1 (Ser334)
Phospho-LKB1 (Ser428)
LXR-β
Malic Enzyme
MDH2
Mios
Mitofusin-1
Mitofusin-2
M2O25a/CA B39
MPC1
MRP2/ABCC2
MTAP
mTOR
Phospho-mTOR (Ser2448)
Phospho-mTOR (Ser2481)
NBC1/SLC4A4
NME1/NDKA
NPC1L1
NQO1
NRF1
OGDH
OGT
p70 S6 Kinase
Phospho-p70 S6 Kinase (Thr371)
Phospho-p70 S6 Kinase (Thr389)
Phospho-p70 S6 Kinase (Thr389/Thr421/Ser424)
Phospho-p70 S6 Kinase (Thr421/Ser424)
p70 S6 Kinase 2
PANK4
PASK
PKC1
PKC2
PDHK1
PDK1
Phospho-PDK1 (Ser241)
Pdx1
Perilipin
PFKFB2
Phospho-PFKFB2 (Ser483)
PFKFB3
PFKL
PFKP
PGAM1
PGC-1α
PGD
PHGDH
PI3 Kinase p55
PI3 Kinase p85α
Phospho-PI3 Kinase p85α (Tyr458)/p55 (Tyr199)
PI3 Kinase p101
PI3 Kinase p110α
PI3 Kinase p110β
PI3 Kinase p110γ
PI3 Kinase Class II α
PI3 Kinase Class III
PI4 Kinase
PT1/SLC20A1
PKM1
PKM1/2
PKM2
Phospho-PKM2 (Tyr105)
PRAS40
Phospho-PRAS40 (Ser138)
Phospho-PRAS40 (Thr246)
Prdx1
Phospho-Prdx1 (Tyr194)
Protor2
PTEN
Phospho-PTEN (Ser380)
Phospho-PTEN (Ser380/Thr382/383)
Non-phospho-PTEN (Ser380/Thr382/383)
PTP1B
Pyruvate Dehydrogenase
RagA
RagB
RagC
RagD
Raptor
Phospho-Raptor (Ser792)
REDD1
Rheb
Rictor
Phospho-Rictor (Thr1135)
SCAP
SCD1
SDHA
SGK1
Phospho-SGK1 (Ser78)
SGK2
SGK3
Phospho-SGK3 (Thr320)
SGLT1
SGLT2
SHMT1
SHMT2
SIN1
Phospho-SIN1 (Thr86)
SNARK/NUAK2
SOD2
SIAR
Succinyl-CoA Synthetase
Synip
Thioredoxin 1
Thioredoxin 2
Thymidine Kinase
Thymidylate Synthase
Tom20
TORC2/CRTC2
Transketolase
TRXR1
TRXR2/TXNRD2
Hamartin/TSC1
Tuberin/TSC2
Phospho-Tuberin/TSC2 (Ser939)
Phospho-Tuberin/TSC2 (Ser1254)
Phospho-Tuberin/TSC2 (Ser1387)
Phospho-Tuberin/TSC2 (Thr1462)
Phospho-Tuberin/TSC2 (Tyr1571)
Tug
Tyrosinase
xCT/SLC7A11
AMP-activated protein kinase (AMPK) is a serine/threonine kinase that acts as a central regulator of energy metabolism. AMPK is activated by increases in the ratio of AMP and ADP to ATP as a result of cellular or environmental stresses such as low glucose, hypoxia, heat shock, or ischemia. Active AMPK positively regulates signaling pathways that replenish ATP supplies—such as insulin-stimulated glucose uptake via Glut4, increased fatty acid oxidation by ACC, or increased glycolysis by PFK2. Concurrently, AMPK negatively regulates proteins central to ATP-consuming processes such as mTORC1, glycogen synthase, SREBP-1, and TSC2, resulting in down-regulation of gluconeogenesis and inhibition of glycogen, lipid, and protein synthesis.

AMPK plays a role in many human diseases. As a critical mediator of glucose and lipid metabolism, AMPK is an important therapeutic target for type 2 diabetes (T2D), a disease characterized by insulin resistance and inadequate glucose uptake. Several direct and indirect AMPK activators, such as metformin, resveratrol, and the thiazolidinediones (TZDs), are currently prescribed for T2D to reduce blood glucose levels and increase insulin sensitivity. In the heart, AMPK regulates cardiac metabolism and the ATP production necessary to maintain normal cardiac contraction. AMPK has been found to have a protective effect during cardiac stress by regulating ATP levels after minor ischemic injury. In addition, mutations in the AMPKγ2 subunit are associated with Wolff-Parkinson-White syndrome, a form of heart disease commonly associated with hypertrophy and excessive glycogen storage in cardiac myocytes. AMPK also plays a role in cancer due to the fact that its upstream kinase, LKB1, is a tumor suppressor. Loss-of-function mutations in LKB1 have been identified in many cancers, including non-small cell lung cancer, cervical cancer, and melanomas. AMPK’s ability to restrict protein synthesis and cell growth through inhibition of mTORC1 makes it an attractive therapeutic target for cancer. In support of this, some AMPK activators such as metformin have been shown to delay tumor onset or be associated with a lower rate of tumorigenesis.

**TARGET LOCALIZATION**

Primary antibodies to assess key protein targets within the AMPK pathway

**QUANTITATIVE ASSAYS**

PathScan® Sandwich ELISA Kits for quantitative analysis

PathScan® Phospho-AMPKα (Thr172) Sandwich ELISA Kit #7959: Treatment of C2C12 cells with H₂O₂ stimulates phosphorylation of AMPKα at Thr172, detected by #7959. C2C12 cells (80–90% confluent) were untreated or treated with H₂O₂ (10 mM, 10 min, 37°C). The absorbance readings at 450 nm are shown in the left figure, while the corresponding western blots using AMPKα (23A3) Rabbit mAb #2603 (right panel) or Phospho-AMPKα (Thr172) (D79.5E) Rabbit mAb #4188 (left panel) are shown in the right figure.

**ANTIBODY SAMPLER KITS**

For convenient investigation of multiple targets within a single pathway. Visit our website for a complete listing of Antibody Sampler Kits.

#12589 Adipogenesis Marker Antibody Sampler Kit
#9957 AMPK and ACC Antibody Sampler Kit
#8335 Fatty Acid and Lipid Metabolism Antibody Sampler Kit
#8350 Phospho-TSC2 Antibody Sampler Kit

**Lipid Metabolism**

Acetyl-CoA is produced in the mitochondria during the metabolic breakdown of both glucose and fatty acids. Newly generated acetyl-CoA combines with oxaloacetate to produce citrate, which progresses through the Krebs cycle to generate ATP and replenish Krebs cycle intermediates. When fatty acid production is necessary, citrate can exit the mitochondria and be converted back into acetyl-CoA in the cytosol through the action of Acetyl-CoA carboxylase (ACL). Acetyl-CoA carboxylase (ACC) then catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis. This reaction is tightly controlled through inhibitory phosphorylations by AMPK and PKA, linking synthesis of new fatty acids to nutrient availability. Fatty acid synthesis is mediated through the action of fatty acid synthase (FAS). The fatty acids produced through these reactions are the building blocks for triglycerides, which are eventually exported to adipocytes and stored to meet future energy demands.

Fatty Acid Synthase (C20G5) Rabbit mAb #3180: Confocal IF analysis of HeLa cells using #3180 (green). Actin filaments were labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5® (fluorescent DNA dye).
Pancreatic β-cells work to maintain glucose homeostasis by releasing insulin into the bloodstream in response to glucose-sensing pathways throughout the body. Insulin stimulates glucose uptake from blood into skeletal muscle, cardiac muscle, and adipose tissue through a signaling cascade mediated by the insulin receptor (IR). Insulin binding to the IR results in activation of the insulin receptor substrate (IRS) protein and subsequent signaling to the PI3K/Akt and Erk1/2 pathways, resulting in translocation of Glut4 from intracellular vesicles to the plasma membrane, glucose uptake, cell proliferation, and survival. Liver is also an insulin-sensitive tissue that takes up glucose via Glut2.

Aberrant insulin signaling is most often linked with type 2 diabetes (T2D), a disease characterized by insulin resistance and inadequate glucose uptake affecting nearly 350 million people worldwide. Current treatment strategies fall into a number of classes based on their mechanism of action: insulin analogs (e.g., insulin glargine); direct and indirect AMPK activators (e.g., metformin, resveratrol, and the thiazolidinediones); inducers of β-cell insulin release (e.g., sulfonylureas and GLP-1 receptor agonists); and exercise, which directly increases Glut4 translocation and glucose uptake in skeletal muscle. Insulin resistance tends to be inextricably linked with obesity; elevated insulin levels induce fat storage in adipocytes and lead to weight gain, while increased fat deposits secrete TNFα and other inflammatory cytokines that further induce insulin resistance. Insulin resistance is also linked to elevated serum triglycerides, hypertension, and high HDL cholesterol levels, which together form the defining characteristics of metabolic syndrome. In addition, insulin resistance is also associated with cardiovascular disease, due to the effect of insulin on vasodilation.

The insulin-like growth factor-I receptor (IGF-IR) is similar in structure to the IR and can exist as either a homodimer or as an IGF-IR/IR heterodimer. IGF-IR uses a similar signaling cascade to promote cell proliferation and survival. IGF-IR overexpression has been identified in many forms of cancer and constitutive signaling has been found to be an important contributor to the initiation and growth of tumor cells.
**TARGET LOCALIZATION**

Primary antibodies to assess localization and expression of key targets

**QUANTITATIVE ASSAYS**

PathScan® Sandwich ELISA Kits for quantitative analysis

**COMPANION REAGENTS**

Recombinant growth factors to induce signaling

**ANTIBODY SAMPLER KITS**

For convenient investigation of multiple targets within a single pathway. Visit our website for a complete listing of Antibody Sampler Kits.

- #8338  Phospho-Insulin/IGF Receptor Antibody Sampler Kit
- #3015  Insulin Receptor Substrate Antibody Sampler Kit
- #12879  IRS-1 Inhibition Antibody Sampler Kit

---

**Select Reviews:**

Normal cells typically generate ATP by metabolizing glucose via glycolysis followed by oxidative phosphorylation in the mitochondria. However, in the 1920s, Otto Warburg observed that tumor cells produce energy by unusually high rates of glycolysis and lactate fermentation (without subsequent cycling through oxidative phosphorylation). This phenomenon is known as aerobic glycolysis or the Warburg effect. In addition to high glycolytic rates, tumor cells also display an increased dependence on glutamine metabolism, fatty acid synthesis, and the pentose phosphate shunt (PPS), which together produce the nucleotides, lipids, and Krebs cycle intermediates necessary for rapid cell growth.

The altered metabolism of cancer cells is controlled by aberrant expression of oncogenes and tumor suppressors within several signaling pathways that regulate the transcription and activity of key metabolic enzymes. For example, the Akt, Erk1/2, and AMPK pathways control the activity (while Myc regulates the transcription) of several glycolytic enzymes such as hexokinase, phosphofructokinase (PFK), and pyruvate kinase isoform M2 (PKM2). In addition, p53 is a transcriptional regulator of targets important for glutaminolysis and the PPS.

Because ATP generation by glycolysis alone produces significantly less ATP per glucose molecule than oxidative phosphorylation, tumor cells consume and metabolize large quantities of glucose. This glucose “addiction” has been targeted by researchers as a point of therapeutic intervention. A number of metabolism-targeting drugs are currently under clinical consideration, including glucose transporter inhibitors, glucose mimetics such as 2-DG that are unable to be metabolized, the AMPK inhibitor metformin, and inhibitors of the glycolytic enzymes hexokinase II, PFK, PKM2, and LDH-A. Use of these agents is currently being evaluated alone and in combination with chemotherapy or other targeted, small-molecule inhibitors.

TARGET LOCALIZATION

Primary antibodies to investigate the expression or localization of key metabolic enzymes

ANT2/SLC25A5 (E2B90) Rabbit mAb #14671: WB analysis of extracts from various cell lines (A) using #14671, IDH1 (D2H1) Rabbit mAb #8137: Confocal IF analysis of 293T cells (B) using #8137 (green). Blue pseudocolor = DNAAP® #4084 (fluorescent DNA dye). Hexokinase II (G645S) Rabbit mAb #2867: IHC analysis of paraffin-embedded human lung carcinoma (C) using #2867. PKM2 (D7BA4) XP® Rabbit mAb #4053; IHC analysis of paraffin-embedded human lung carcinoma (D) using #4053.

QUANTITATIVE ASSAYS

ChIP-validated kits, primers, and antibodies to examine protein-DNA interactions

Glucose-6-Phosphate Dehydrogenase Activity Assay Kit to assess the rate-limiting step in the pentose phosphate pathway

Glucose-6-Phosphate Dehydrogenase (G6PD) Activity Assay Kit #12561: The relationship between the protein concentration of lysates from untreated and G6PD inhibitor DHEA (0.5 mM) treated Jurkat cells and relative fluorescence (RFU) is shown. The G6PD inhibitor DHEA can effectively inhibit this chain reaction as shown in this figure.

- Jurkat control
- Jurkat + 0.5 mM DHEA

Pathways in Human Cancer Poster

Order your free copy at www.cellsignal.com/cancerpc
The serine/threonine kinase Akt exists as three isoforms in mammals. Akt1 and Akt2 have a widespread tissue distribution, whereas Akt3 is expressed in testes and brain. Akt regulates many important biological processes including cell survival, proliferation, growth, and glycogen metabolism. Various growth factors, hormones, and cytokines activate Akt by binding their cognate receptor tyrosine kinase (RTK), cytokine receptor, or G protein-coupled receptor (GPCR). This triggers activation of the lipid kinase PI3K, which generates PIP3 to draw Akt to the plasma membrane. Akt is then activated through dual phosphorylation at Thr308 by PDK1 and Ser473 by mTORC2.

Akt phosphorylates a large number of downstream targets that mediate its metabolic and mitogenic effects. Akt plays an important role in signaling through the insulin receptor, and inappropriate Akt activation can result in the insulin resistance associated with type 2 diabetes (T2D), metabolic syndrome, and some forms of obesity. Akt directly mediates the effects of insulin, including Glut4 translocation and glucose uptake (through phosphorylation of AS160 and TBC1D1), activation of protein synthesis and growth via mTORC1, and inhibition of gluconeogenesis in the liver. Akt also regulates general glucose and lipid metabolism. Active Akt phosphorylates GSK-3 to increase glycogen synthesis, the enzymes hexokinase and phosphofructokinase to increase glycolysis, and ATP-citrate lyase to increase fatty acid synthesis.

The profound effects of Akt on cell proliferation and survival have made it a central focus of cancer research. Akt inhibits the cell cycle inhibitors Wee1, p27 Kip1, and p21 Cip1 to promote cell proliferation. Akt prevents apoptosis through inhibition of several pro-apoptotic factors such as Bim, Bax, Bad, and FoxO1. Akt also activates the apoptosis inhibitor protein, XIAP, and blocks p53-mediated apoptosis through stabilization of MDM2. Activating mutations in PI3K3C (a subunit of PI3K), and loss-of-function mutations in PTEN both upregulate Akt activity and are some of the most commonly mutated genes in cancer.

TARGET LOCALIZATION

Primary antibodies to assess localization and expression of Akt and its targets

Phospho-Akt1 (Ser473) (D7F10) XP® Rabbit mAb (Akt1 Specific) #9018: WB analysis of extracts from Akt1 (-/-) mouse embryonic fibroblasts (MEFs) or Akt2 (-/-) MEFs, untreated or stimulated with hPDGF #6913 (100 ng/ml, 15 min), (A) using #9018 (upper), Phospho-Akt (Ser473) (DIE) XP® Rabbit mAb #4060 (middle), or Akt (pan) (C67E7) Rabbit mAb #4691 (lower).

Phospho-mTOR (Ser2448) (D9C2) XP® Rabbit mAb #5536: WB analysis of extracts from serum-starved NIH/3T3 cells, untreated or insulin-treated (150 nM, 5 min), alone or in combination with λ-phosphatase (B), using #5536 (upper) or mTOR (7C10) Rabbit mAb #2983 (lower).

GSK-3β (D5C5Z) XP® Rabbit mAb #12456: Confocal IF analysis of wild-type mouse embryonic fibroblasts (MEFs) (C), GSK-3α (-/-) MEFs (D), and GSK-3β (-/-) MEFs (E) using #12456 (green). Actin filaments were labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye). (MEF wild type, GSK-3α (-/-), and GSK-3β (-/-) cells were kindly provided by Dr. Jim Woodgett, University of Toronto, Canada).

QUANTITATIVE ASSAYS

PathScan® Sandwich ELISA Kits for quantitative analysis of Akt activation

PathScan® Phospho-Akt (Thr308) Chemiluminescent Sandwich ELISA Kit #7135: Relationship between protein concentration of lysates from untreated and PDGF-treated NIH/3T3 cells and immediate light generation with chemiluminescent substrate is shown. Cells (at 80% confluence) were treated with PDGF (50 ng/ml) and lysed after incubation at 37°C for 5 min. Graph inset corresponding to the shaded area shows high sensitivity and a linear response at the low protein concentration range.

Technical Support

At CST, providing exceptional customer service and technical support are top priorities. Our scientists work at the bench daily to produce and validate our antibodies, so they have hands-on experience and in-depth knowledge of each antibody’s performance. In the process, these same scientists generate valuable reference information that they use to answer your questions and help troubleshoot your experiment by phone or email.

USA & Europe:
www.cellsignal.com/support

China:
www.cst-c.com.cn/support

Japan:
www.cstj.co.jp/support

© 2015 Cell Signaling Technology, Inc.
Cell Signaling Technology, CST, PathScan, PTMScan, SignalSilence, SimpleChIP, SimpleChIP Plus, and XP are trademarks of Cell Signaling Technology, Inc. DRAQ5 is a registered trademark of Biostatus Limited. LI-COR and LI-COR Biosciences Odyssey are registered trademarks of LI-COR Biosciences Inc.
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community. Our 400 employees operate worldwide from our headquarters in Danvers, Massachusetts, and our offices in the Netherlands, China, and Japan. As scientists ourselves, we believe an antibody is only as good as the research it enables. For this reason, we are actively engaged in the development of technologies to facilitate signaling analysis and mechanistic cell biology research. And, the same scientists who produce and validate our primary antibodies are available to provide technical support for customers. In this way, we are able to supply customers with both the reagents and the information they need to achieve consistent, reliable results at the research bench.

CST Antibody Performance Guarantee: To learn more, please visit: www.cellsignal.com/abguarantee.